Physostigmine-atropine solution fails to reverse diazepam sedation

Area of Science:

• Anesthesiology and Pharmacology
• Neuroscience and Sedation Management

Background:

• Intravenous diazepam is commonly used for conscious sedation in dental procedures.
• Physostigmine, a cholinesterase inhibitor, has been anecdotally reported to reverse benzodiazepine-induced sedation.

Purpose of the Study:

• To investigate the efficacy of physostigmine in reversing diazepam-induced sedation in patients undergoing dental extraction.
• To evaluate the impact of physostigmine on psychomotor function and patient recovery after diazepam sedation.

Main Methods:

• A randomized, placebo-controlled study involving patients undergoing dental extraction under intravenous diazepam sedation.
• Psychomotor function was assessed using a modified Bender-Gestalt Dot Test.
• Patient and surgeon recovery assessments were scored on a 0-10 scale following administration of either a physostigmine-atropine mixture or saline.

Main Results:

• The physostigmine-atropine mixture did not significantly accelerate recovery compared to the saline placebo.
• No significant improvement in psychomotor function was observed in the physostigmine group versus the saline group.
• Patient and surgeon self-assessments of recovery showed no significant difference between the two treatment groups.

Conclusions:

• Physostigmine is not effective in reversing diazepam-induced sedation in the context of dental surgery.
• The analeptic effect of physostigmine may be limited to anticholinergic drug-induced sedation, not benzodiazepines.
• Further research is needed to clarify the specific mechanisms and applications of physostigmine as an antidote.